Loomis, Sayles & Company
IMCR icon

Loomis, Sayles & Company’s Immunocore IMCR Stock Holding History

Loomis, Sayles & Company’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-301,815
Closed -$10.2M – 716
2024
Q2 		$10.2M Buy
301,815
+282,817
+1,489% +$14.4M 0.01% 354
2024
Q1 		$1.23M Buy
+18,998
New +$1.3M ﹤0.01% 454

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Loomis, Sayles & Company's IMCR Position: Q3 2024 in Review

Loomis, Sayles & Company sold out of Immunocore (IMCR) in Q3 2024, closing a stake of 301,815 shares — an estimated $10.2M sold.

Loomis, Sayles & Company first reported a position in IMCR in Q1 2024 and held it in 2 quarters. The position peaked at $10.2M in Q2 2024. 130 funds tracked by Wall St. Rank hold IMCR as of Q3 2024.

  • Loomis, Sayles & Company reported no remaining Immunocore position as of Q3 2024 after selling out during the quarter.
  • Loomis, Sayles & Company sold 301,815 Immunocore shares in Q3 2024, an estimated $10.2M.
  • Loomis, Sayles & Company first reported a position in Immunocore in Q1 2024 and held it in 2 quarters.
  • Loomis, Sayles & Company's Immunocore position peaked at $10.2M in Q2 2024.
  • 130 funds tracked by Wall St. Rank held Immunocore as of Q3 2024.

Based on Loomis, Sayles & Company's 13F filing for Q3 2024, filed 13 Nov 2024.